Fig. 1
From: CXCL13 chemokine as a promising biomarker to diagnose neurosyphilis in HIV-negative patients
Scatterplot of serum CXCL13 concentrations (a), CSF CXCL13 concentrations (b) and QCXCL13 (c) in different groups which was used a logarithmic scale for the Y-axis. a The concentrations of CXCL13 in serum were statistically different among the five groups. The concentrations in the healthy group were statistically lower than the other four groups (P < 0.001). The concentrations in syphilis/non-neurosyphilis were statistically lower than non-syphilis/other CNS infection group (P = 0.022). The concentrations in neurosyphilis group were higher than syphilis/non-neurosyphilis group, but there was no statistical difference (P = 0.084). b The concentrations of CXCL13 in CSF were statistically different among the four groups. The concentrations in the neurosyphilis group were statistically higher than the syphilis/non-neurosyphilis (P < 0.001), and non-syphilis/non CNS infection group (P = 0.009). c The QCXCL13 in CSF were statistically different among the four groups. The QCXCL13 in the neurosyphilis group were statistically higher than the syphilis/non-neurosyphilis (P = 0.001), and non-syphilis/non CNS infection group (P = 0.003)